CAMBRIDGE, Mass. – Moderna Inc. says it has begun the process to win full U.S. regulatory approval for the use of its COVID-19 vaccine in adults.
The pharmaceutical company announced Tuesday it has begun a “rolling submission” to the U.S. Food and Drug Administration of data from its studies of the two-dose vaccine.
Moderna’s vaccine already has been cleared for emergency use by the FDA and regulators in numerous other countries. So far, more than 124 million doses have been administered in the United States.
Large-scale studies of the shots continued after Moderna’s emergency authorization. The FDA will scrutinize the information to see if the vaccine meets stringent criteria for full licensure.
Moderna is the second COVID-19 vaccine maker to seek full approval, following Pfizer Inc. and German partner BioNTech.
Last week, Moderna also announced that its vaccine appears safe and effective in kids as young as 12. The company plans to seek emergency authorization for teen use this month.
